Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SLN Stock Forecast 2025-2026
$4.40
Current Price
$191.28M
Market Cap
Buy 6
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to SLN Price Targets
+1,606.5%
To High Target of $75.00
+582.6%
To Median Target of $30.00
-31.7%
To Low Target of $3.00
SLN Price Momentum
+18.6%
1 Week Change
+39.8%
1 Month Change
-80.9%
1 Year Change
-36.2%
Year-to-Date Change
-81.6%
From 52W High of $23.92
+123.1%
From 52W Low of $1.97
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Silence Therapeutics (SLN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SLN and similar high-potential opportunities.
Latest SLN Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SLN has a bullish consensus with a median price target of $30.00 (ranging from $3.00 to $75.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $4.40, the median forecast implies a 582.6% upside. This outlook is supported by 6 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,606.5% upside. Conversely, the most conservative target is provided by Richard Law at Goldman Sachs, suggesting a 31.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLN Analyst Ratings
6
Buy
0
Hold
1
Sell
SLN Price Target Range
Low
$3.00
Average
$30.00
High
$75.00
Current: $4.40
Latest SLN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $35.00 |
| May 9, 2025 | Goldman Sachs | Richard Law | Sell | Maintains | $3.00 |
| May 9, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $25.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Mar 5, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $45.00 |
| Mar 4, 2025 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $25.00 |
| Mar 4, 2025 | Goldman Sachs | Richard Law | Sell | Maintains | $4.00 |
| Feb 11, 2025 | Goldman Sachs | Richard Law | Sell | Initiates | $6.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Jan 29, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Dec 10, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
| Dec 9, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 14, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
| Oct 8, 2024 | Morgan Stanley | Michael Ulz | Overweight | Reiterates | $49.00 |
| Aug 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Aug 16, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
| Jun 28, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
| Jun 28, 2024 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $49.00 |
Silence Therapeutics plc ADR (SLN) Competitors
The following stocks are similar to Silence Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SLN
Silence Therapeutics
mkt cap
191.28M
Silence Therapeutics plc ADR (SLN) Financial Data
Silence Therapeutics plc ADR has a market capitalization of $191.28M with a P/E ratio of -4.4x. The company generates $43.26M in trailing twelve-month revenue with a -104.7% profit margin.
Revenue growth is +1,180.6% quarter-over-quarter, while maintaining an operating margin of +26.5% and return on equity of -58.1%.
Valuation Metrics
Market Cap
$191.28M
Enterprise Value
$357.14M
P/E Ratio
-4.4x
PEG Ratio
0.3x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+1,180.6%
Gross Margin
+62.0%
Operating Margin
+26.5%
Net Margin
-104.7%
EPS Growth
-99.3%
Financial Health
Cash/Price Ratio
+23.7%
Current Ratio
11.1x
Debt/Equity
0.1x
ROE
-58.1%
ROA
-19.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Silence Therapeutics plc ADR (SLN) Business Model
About Silence Therapeutics plc ADR
What They Do
Biotechnology company developing RNA interference therapeutics.
Business Model
Silence Therapeutics utilizes its proprietary GalNAc targeting platform to develop RNAi therapeutics that inhibit disease-causing genes. The company generates revenue through collaborations with large pharmaceutical firms and potentially through the commercialization of its innovative therapies, particularly in rare diseases and oncology.
Additional Information
The company is positioned as a leader in RNAi technology, which could significantly impact the management of genetic disorders. As an ADR, it provides American investors with access to international equity, enhancing portfolio diversification.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
116
CEO
Mr. Craig A. Tooman M.B.A.
Country
United Kingdom
IPO Year
1996
Website
www.silence-therapeutics.comSilence Therapeutics plc ADR (SLN) Latest News & Analysis
Latest News
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
9 days ago
Quick Summary
Silence Therapeutics plc (Nasdaq: SLN) reported strong Q1 2025 results, emphasizing progress in clinical and operational efforts in developing novel siRNA therapies.
Why It Matters
Strong financial results and operational execution from Silence Therapeutics signal potential growth in the siRNA therapy market, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Silence Therapeutics plc has appointed Tim McInerney to its Board of Directors, effective immediately. He will be up for re-appointment at the AGM in June 2025.
Why It Matters
The appointment of Tim McInerney to Silence Therapeutics' Board signals potential strategic shifts and expertise, which could influence the company's direction and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, potentially boosting the stock price.
Why It Matters
Silence Therapeutics' upgrade to a Zacks Rank #2 indicates improved earnings expectations, potentially boosting investor confidence and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
2 months ago
Quick Summary
Silence Therapeutics plc ($SLN) will present a company overview at the Leerink Partners Global Healthcare Conference on March 12 at 1:00 p.m. ET. The event will be accessible via their website.
Why It Matters
Silence Therapeutics' presentation at a major healthcare conference could influence investor sentiment and stock performance, highlighting its developments in siRNA therapies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Silence Therapeutics plc (NASDAQ: SLN) will hold its Q4 2024 earnings call on February 27, 2025, at 8:00 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters
Earnings calls provide key insights into a company's financial health and future strategy, influencing stock performance and investor sentiment. Silence Therapeutics' upcoming call is crucial for assessing its market position.
Source: Seeking Alpha
Market Sentiment:
Neutral
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
2 months ago
Quick Summary
Silence Therapeutics plc (Nasdaq: SLN) reported its 2024 financial results, showcasing strong clinical progress and advancements in its mRNAi GOLD™ platform for developing siRNA therapies.
Why It Matters
Silence Therapeutics' strong clinical execution and pipeline advancements signal potential growth, making it a key player in the RNA therapy sector, which might attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SLN Stock
What is Silence Therapeutics plc ADR's (SLN) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Silence Therapeutics plc ADR (SLN) has a median price target of $30.00. The highest price target is $75.00 and the lowest is $3.00.
Is SLN stock a good investment in 2025?
According to current analyst ratings, SLN has 6 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $4.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLN stock?
Wall Street analysts predict SLN stock could reach $30.00 in the next 12 months. This represents a 582.6% increase from the current price of $4.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Silence Therapeutics plc ADR's business model?
Silence Therapeutics utilizes its proprietary GalNAc targeting platform to develop RNAi therapeutics that inhibit disease-causing genes. The company generates revenue through collaborations with large pharmaceutical firms and potentially through the commercialization of its innovative therapies, particularly in rare diseases and oncology.
What is the highest forecasted price for SLN Silence Therapeutics plc ADR?
The highest price target for SLN is $75.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,606.5% increase from the current price of $4.40.
What is the lowest forecasted price for SLN Silence Therapeutics plc ADR?
The lowest price target for SLN is $3.00 from Richard Law at Goldman Sachs, which represents a -31.7% decrease from the current price of $4.40.
What is the overall SLN consensus from analysts for Silence Therapeutics plc ADR?
The overall analyst consensus for SLN is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $30.00.
How accurate are SLN stock price projections?
Stock price projections, including those for Silence Therapeutics plc ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 2:07 AM UTC